دورية أكاديمية
The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
| العنوان: | The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting. |
|---|---|
| المؤلفون: | Lawler C; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina., Gu L; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina.; Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina., Howard LE; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina.; Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina., Branche B; Department of Urology, Virginia Commonwealth University School of Medicine, Richmond, Virginia., Wiggins E; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina., Srinivasan A; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina.; Division of Urology, The University of Texas Medical Branch, Galveston, Texas., Foster ML; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina., Klaassen Z; Section of Urology, Department of Surgery, Augusta University-Medical College of Georgia, Augusta, Georgia., De Hoedt AM; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina., Gingrich JR; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina., Theodorescu D; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Freedland SJ; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina.; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.; Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California., Williams SB; Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina.; Division of Urology, The University of Texas Medical Branch, Galveston, Texas. |
| المصدر: | Cancer [Cancer] 2021 Nov 01; Vol. 127 (21), pp. 3998-4005. Date of Electronic Publication: 2021 Jul 08. |
| نوع المنشور: | Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
| مواضيع طبية MeSH: | Urinary Bladder Neoplasms*, Adjuvants, Immunologic ; Administration, Intravesical ; BCG Vaccine/therapeutic use ; Humans ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/drug therapy ; Progression-Free Survival ; Proportional Hazards Models ; Urinary Bladder |
| مستخلص: | Background: The objective of this study was to describe bladder cancer outcomes as a function of race among patients with high-risk non-muscle-invasive bladder cancer (NMIBC) in an equal-access setting. Methods: A total of 412 patients with high-risk NMIBC who received bacille Calmette-Guérin (BCG) from January 1, 2010, to December 31, 2015, were assessed. The authors used the Kaplan-Meier method to estimate event-free survival and Cox regression to determine the association between race and recurrence, progression, disease-specific, and overall survival outcomes. Results: A total of 372 patients who had complete data were included in the analysis; 48 (13%) and 324 (87%) were Black and White, respectively. There was no difference in age, sex, smoking status, or Charlson Comorbidity Index by race. White patients had a higher socioeconomic status with a greater percentage of patients living above the poverty level in comparison with Black patients (median, 85% vs 77%; P < .001). A total of 360 patients (97%) received adequate induction BCG, and 145 patients (39%) received adequate maintenance BCG therapy. There was no significant difference in rates of adequate induction or maintenance BCG therapy according to race. There was no significant difference in recurrence (hazard ratio [HR], 1.53; 95% confidence interval [CI], 0.64-3.63), progression (HR, 0.77; 95% CI, 0.33-1.82), bladder cancer-specific survival (HR, 1.01; 95% CI, 0.30-3.46), or overall survival (HR, 0.97; 95% CI, 0.56-1.66) according to Black race versus White race. Conclusions: In this small study from an equal-access setting, there was no difference in the receipt of BCG or any differences in bladder cancer outcomes according to race. (© 2021 American Cancer Society.) |
| References: | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30. doi:10.3322/caac.21590. Mertens LS, Neuzillet Y, Horenblas S, van Rhijn BW. Landmarks in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:476-480. doi:10.1038/nrurol.2014.130. Seo M, Langabeer JR II. Demographic and survivorship disparities in non-muscle-invasive bladder cancer in the United States. J Prev Med Public Health. 2018;51:242-247. doi:10.3961/jpmph.18.092. Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology. 2011;78:544-549. doi:10.1016/j.urology.2011.02.042. Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. Urol Oncol. 2012;30:81-88. doi:10.1016/j.urolonc.2011.08.011. Schinkel JK, Shao S, Zahm SH, McGlynn KA, Shriver CD, Zhu K. Overall and recurrence-free survival among Black and White bladder cancer patients in an equal-access health system. Cancer Epidemiol. 2016;42:154-158. doi:10.1016/j.canep.2016.04.012. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. doi:10.3322/caac.21551. Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34:1935-1944. doi:10.1200/jco.2015.64.4070. Final Report to the Secretary of Defense: Military Health System Review. US Department of Defense. Published August 29, 2014. Accessed May 24, 2021. https://www.pdhealth.mil/final-report-secretary-defense-military-health-system-review-august-2014. Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14:244-255. doi:10.1038/nrurol.2017.16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. doi:10.1016/0021-9681(87)90171-8. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93-99. doi:10.3322/caac.21388. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle-invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021-1029. doi:10.1016/j.juro.2016.06.049. Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. Eur Urol. 2019;76:639-657. doi:10.1016/j.eururo.2019.08.016. Compérat E, Varinot J, Moroch J, Eymerit-Morin C, Brimo F. A practical guide to bladder cancer pathology. Nat Rev Urol. 2018;15:143-154. doi:10.1038/nrurol.2018.2. Amin MB, McKenney JK, Paner GP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol. 2013;63:16-35. doi:10.1016/j.eururo.2012.09.063. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e20-e34. doi:10.1097/pas.0000000000000240. Barocas DA, Alvarez J, Koyama T, et al. Racial variation in the quality of surgical care for bladder cancer. Cancer. 2014;120:1018-1025. doi:10.1002/cncr.28520. Cole AP, Fletcher SA, Berg S, et al. Impact of tumor, treatment, and access on outcomes in bladder cancer: can equal access overcome race-based differences in survival? Cancer. 2019;125:1319-1329. doi:10.1002/cncr.31926. Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011;185:1631-1636. doi:10.1016/j.juro.2010.12.049. Williams SB, Huo J, Kosarek CD, et al. Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. Cancer Causes Control. 2017;28:755-766. doi:10.1007/s10552-017-0902-2. Wang Y, Chang Q, Li Y. Racial differences in urinary bladder cancer in the United States. Sci Rep. 2018;8:12521. doi:10.1038/s41598-018-29987-2. Sung JM, Martin JW, Jefferson FA, et al. Racial and socioeconomic disparities in bladder cancer survival: analysis of the California Cancer Registry. Clin Genitourin Cancer. 2019;17:e995-e1002. doi:10.1016/j.clgc.2019.05.008. Gidwani-Marszowski R, Faricy-Anderson K, Asch SM, Illarmo S, Ananth L, Patel MI. Potentially avoidable hospitalizations after chemotherapy: differences across Medicare and the Veterans Health Administration. Cancer. 2020;126:3297-3302. doi:10.1002/cncr.32896. Deswal A, Petersen NJ, Souchek J, Ashton CM, Wray NP. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol. 2004;43:778-784. doi:10.1016/j.jacc.2003.10.033. Okike K, Chan PH, Prentice HA, Navarro RA, Hinman AD, Paxton EW. Association of race and ethnicity with total hip arthroplasty outcomes in a universally insured population. J Bone Joint Surg Am. 2019;101:1160-1167. doi:10.2106/JBJS.18.01316. Freedland SJ, Vidal AC, Howard LE, et al. Race and risk of metastases and survival after radical prostatectomy: results from the SEARCH database. Cancer. 2017;123:4199-4206. doi:10.1002/cncr.3083. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639-653. doi:10.1016/j.eururo.2013.06.003. |
| معلومات مُعتمدة: | W81XWH1710576 U.S. Department of Defense |
| فهرسة مساهمة: | Keywords: bladder cancer; disparities; noninvasive; progression; race; recurrence; survival; treatment |
| المشرفين على المادة: | 0 (Adjuvants, Immunologic) 0 (BCG Vaccine) |
| تواريخ الأحداث: | Date Created: 20210708 Date Completed: 20220309 Latest Revision: 20220309 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/cncr.33792 |
| PMID: | 34237155 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.33792 |